At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 4, 2026 at 16:01 ET
Keros Therapeutics reported a net income of $87.0 million for 2025, a significant improvement from a $187.4 million net loss in 2024, driven primarily by $205.4 million in license revenue from Takeda. The company is advancing rinvatercept into a Phase 2 trial for Duchenne muscular dystrophy in Q2 2026 and plans regulatory engagement for an ALS trial. Cash reserves decreased to $287.4 million from $559.9 million, but the company expects this to fund operations into early 2028.
- Net income of $87.0 million in 2025 vs. $187.4 million net loss in 2024, driven by $205.4 million in license revenue from Takeda
- R&D expenses declined to $129.6 million in 2025 from $173.6 million in 2024 due to transition of elritercept R&D to Takeda
- Cash and cash equivalents dropped to $287.4 million as of Dec 31, 2025 from $559.9 million in 2024, primarily due to share repurchase and tender offer
- Company expects cash runway into first half of 2028
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access